No Data
Hubei Guangji Pharmaceutical Gets Registration Approval for Febuxostat Tablets; Shares Jump 8%
Hubei Guangji Pharmaceutical (000952.SZ) subsidiary Guanghua Pharmaceutical intends to raise capital and introduce no less than two strategic investors.
Hubei Guangji Pharmaceutical (000952.SZ) announced that its wholly-owned subsidiary Hubei Guanghua Pharmaceutical Co., Ltd. ("Guanghua...
Hubei Guangji Pharmaceutical (000952.SZ) has received the approval notification for the supplemental application of Pharmaceutical Acyclovir hydrochloride tablets.
Hubei Guangji Pharmaceutical (000952.SZ) announced that recently, the company received the approval issued by the National Medical Products Administration for the hydrochloride...
Hubei Guangji Pharmaceutical (000952.SZ): Guanghua Pharmaceutical intends to pre-list and introduce strategic investors through capital increase and share expansion.
On November 15, Gelonghui reported that Hubei Guangji Pharmaceutical (000952.SZ) announced that its wholly-owned subsidiary Hubei Guanghua Pharmaceutical Co., Ltd. (hereinafter referred to as "Guanghua Pharmaceutical") intends to pre-list on the Shanghai United Assets and Equity Exchange to introduce strategic investors through capital increase. In order to effectively utilize asset resources and realize asset value, the wholly-owned subsidiary Guanghua Pharmaceutical plans to pre-list on the Shanghai United Assets and Equity Exchange to introduce strategic investors through capital increase. This pre-listing is only for information disclosure purposes, aimed at soliciting interested parties and does not constitute a trading action.
Guangji Pharmaceutical: Report for the third quarter of 2024
hubei guangji pharmaceutical (000952.SZ): a net loss of 0.159 billion yuan in the first three quarters.
October 30th, Guangji Pharmaceutical (000952.SZ) released its third quarter report for 2024, achieving revenue of 0.462 billion yuan in the first three quarters, a decrease of 11.54% year-on-year; net income attributable to shareholders of the listed company was -0.159 billion yuan; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.172 billion yuan; basic earnings per share was -0.4498 yuan.
Hubei Guangji Pharmaceutical Co., Ltd. (SZSE:000952) Surges 25% Yet Its Low P/S Is No Reason For Excitement
